Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone484-453-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions
What is Verrica Pharmaceuticals' stock symbol?
Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."
How were Verrica Pharmaceuticals' earnings last quarter?
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) announced its earnings results on Wednesday, August, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. View Verrica Pharmaceuticals' Earnings History.
When is Verrica Pharmaceuticals' next earnings date?
What price target have analysts set for VRCA?
1 analysts have issued 1-year target prices for Verrica Pharmaceuticals' shares. Their forecasts range from $23.00 to $23.00. On average, they expect Verrica Pharmaceuticals' share price to reach $23.00 in the next twelve months. This suggests a possible upside of 57.0% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.
What is the consensus analysts' recommendation for Verrica Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.
Has Verrica Pharmaceuticals been receiving favorable news coverage?
Press coverage about VRCA stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Verrica Pharmaceuticals.
Are investors shorting Verrica Pharmaceuticals?
Verrica Pharmaceuticals saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 550,100 shares, a decline of 7.3% from the August 15th total of 593,600 shares. Based on an average daily volume of 58,100 shares, the short-interest ratio is currently 9.5 days. Currently, 4.5% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.
Who are some of Verrica Pharmaceuticals' key competitors?
Some companies that are related to Verrica Pharmaceuticals include Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Eidos Therapeutics (EIDX), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), ArQule (ARQL), Innoviva (INVA) and Endo International (ENDP).
What other stocks do shareholders of Verrica Pharmaceuticals own?
Who are Verrica Pharmaceuticals' key executives?
Verrica Pharmaceuticals' management team includes the folowing people:
- Mr. Ted White, Pres, CEO & Director (Age 54)
- Mr. Chris Degnan, Chief Financial Officer (Age 39)
- Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
- Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
- Christopher G. Hayes, Sec.
When did Verrica Pharmaceuticals IPO?
(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.
How do I buy shares of Verrica Pharmaceuticals?
Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Verrica Pharmaceuticals' stock price today?
One share of VRCA stock can currently be purchased for approximately $14.65.
How big of a company is Verrica Pharmaceuticals?
Verrica Pharmaceuticals has a market capitalization of $377.09 million. The company earns $-20,650,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.View Additional Information About Verrica Pharmaceuticals.
What is Verrica Pharmaceuticals' official website?
How can I contact Verrica Pharmaceuticals?
Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]
MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)
MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
